IP Library Granted Patent US 11,583,558
Granted Patent B2
US 11,583,558 · App. 16/804,285 · Granted Feb 21, 2023

Methods and compositions for treatment of microbiome-associated disorders

Inventors: Colleen Cutcliffe (Menlo Park, CA); John S. Eid (San Francisco, CA); Tomer Altman (San Francisco, CA); Orville G. Kolterman (La Jolla, CA); James H. Bullard (San Francisco, CA)
Assignee: PENDULUM THERAPEUTICS, INC.
A61K35/74A61K9/28A61K31/733A61P25/22C12Y207/02007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,583,558
App. No.
16/804,285
Granted
Feb 21, 2023
Kind
B2
Abstract

Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Claims (16)

1. A method of treating a disorder in a subject with the disorder, the method comprising:

administering a therapeutically effective amount of a microbial composition to the subject, wherein the microbial composition comprises two primary fermenter microbes and three secondary fermenter microbes that increase production of butyrate in the subject, and wherein the disorder is hyperalgesia, anxiety, or both.

2. The method of claim 1 , wherein the microbial composition modulates a gut-brain neural circuit in the subject.

3. The method of claim 1 , wherein the microbial composition modulates neurotransmitter production in the subject.

4. The method of claim 1 , wherein the subject has gut dysbiosis.

5. The method of claim 1 , wherein the microbial composition further comprises a pharmaceutically-acceptable carrier.

6. The method of claim 1 , wherein the subject is human.

7. The method of claim 1 , wherein the microbial composition is formulated as an enteric-coated pill.

8. The method of claim 1 , wherein the microbial composition is delivered to an ileum and/or colon region of the subject's gastrointestinal tract.

9. The method of claim 1 , wherein the microbial composition is formulated for oral delivery.

10. The method of claim 1 , wherein the microbial composition further comprises a prebiotic.

11. The method of claim 10 , wherein the prebiotic is selected from the group consisting of: complex carbohydrates, complex sugars, resistant dextrins, resistant starch, amino acids, peptides, nutritional compounds, biotin, polydextrose, fructooligosaccharide (FOS), galactooligosaccharides (GOS), inulin, starch, lignin, psyllium, chitin, chitosan, gums, guar gum, high amylose cornstarch (HAS), cellulose, -glucans, hemi-celluloses, lactulose, mannooligosaccharides, mannan oligosaccharides (MOS), oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, trans-galactooligosaccharide, pectin, xylooligosaccharides (XOS), locust bean gum, P-glucan, methylcellulose, and any combination thereof.

12. The method of claim 10 , wherein the prebiotic is inulin.

13. The method of claim 1 , wherein the primary fermenter microbes and secondary fermenter microbes are obligate anaerobes.

14. The method of claim 1 , wherein the microbial composition comprises Akkermansia muciniphila as a primary fermenter, Bifidobacterium infantis as a primary fermenter, Eubacterium hallii as a secondary fermenter, Clostridium beijerinckii as a secondary fermenter, and Clostridium butyricum as a secondary fermenter.

15. The method of claim 14 , wherein the microbial composition further comprises at least one microbe selected from the group consisting of: Anaerostipes caccae, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, Butyrivibrio fibrisolvens, Clostridium acetobutylicum, Clostridium aminophilum, Clostridium colinum, Clostridium coccoides, Clostridium indolis, Clostridium nexile, Clostridium orbiscindens, Clostridium propionicum, Clostridium xylanolyticum, Enterococcus faecium, Eubacterium rectale, Fibrobacter succino genes, Oscillospira guilliermondii, Roseburia cecicola, Roseburia inulinivorans, Ruminococcus jlavefaciens, Ruminococcus gnavus, Ruminococcus obeum, Stenotrophomonas nitritireducens, Streptococcus cremoris, Streptococcus faecium, Streptococcus infantis, Streptococcus mutans, Streptococcus thermophilus, Anaerofustis stercorihominis, Anaerostipes hadrus, Anaerotruncus colihominis, Clostridium sporogenes, Clostridium tetani, Coprococcus, Coprococcus eutactus, Eubacterium cylindroides, Eubacterium dolichum, Eubacterium ventriosum, Roseburia faeccis, Roseburia hominis, Roseburia intestinalis, Lactobacillus bifidus, Acidaminococcus fermentans, Acidaminococcus intestine, Blautia hydrogenotrophica, Citrobacter amalonaticus, Citrobacter freundii, Clostridium aminobutyricum Clostridium bartlettii, Clostridium cochlearium, Clostridium kluyveri, Clostridium limosum, Clostridium malenominatum, Clostridium pasteurianum, Clostridium peptidivorans, Clostridium saccharobutylicum, Clostridium sporosphaeroides, Clostridium sticklandii, Clostridium subterminale, Clostridium symbiosum, Clostridium tetanomorphum, Eubacterium oxidoreducens, Eubacterium pyruvativorans, Methanobrevibacter smithii, Morganella morganii, Peptoniphilus asaccharolyticus, Peptostreptococcus , and any combination thereof.

Assignments (2)
SECURITY INTEREST Recorded Jan 18, 2022
From: PENDULUM THERAPEUTICS, INC.
To: TRINITY CAPITAL INC.
Reel/Frame 058678/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: CUTCLIFFE, COLLEEN; EID, JOHN S.; ALTMAN, TOMER; KOLTERMAN, ORVILLE G.; BULLARD, JAMES H.
To: PENDULUM THERAPEUTICS, INC.
Reel/Frame 052062/0579 →